Physician profile
Ray Cinnater
NPI 1699759522
$370.59
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.91 | 2019 | |
| Sunovion Pharmaceuticals INC. | $39.95 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $39.54 | 2019 | |
| Allergan, INC. | $38.75 | 2019 | |
| Pfizer INC. | $35.08 | 2019 | |
| Amgen INC. | $28.44 | 2019 | |
| Novo Nordisk INC | $27.64 | 2019 | |
| Csl Behring | $22.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.28 | 2019 | |
| Shire North American Group INC | $17.87 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.58 | 2019 | |
| Mylan Specialty L.P. | $15.31 | 2019 | |
| Amarin Pharma, INC. | $14.64 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Cinnater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.